Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07545356
PHASE1

A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors

Sponsor: Kivu Bioscience Inc.

View on ClinicalTrials.gov

Summary

This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Official title: A Phase 1 Dose-Finding and Dose Optimization-Expansion Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

76

Start Date

2026-06

Completion Date

2029-12

Last Updated

2026-07-10

Healthy Volunteers

No

Conditions

Interventions

DRUG

KIVU-305

KIVU-305 will be administered IV .

Locations (3)

Kivu Trial Site

Sydney, New South Wales, Australia

Kivu Trial Site

Wollongong, New South Wales, Australia

Kivu Trial Site

Brisbane, Queensland, Australia